Amphastar Pharmaceuticals（AMPH）株式概要
バイオ医薬品会社であるアンファスター・ファーマシューティカルズ・インクは、米国、中国、フランスにおいて、ジェネリック医薬品および独自の注射剤、吸入剤、経鼻剤の開発、製造、販売、マーケティングを行っている。 詳細
AMPH Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amphastar Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$16.87 |
| 52週高値 | US$31.26 |
| 52週安値 | US$16.76 |
| ベータ | 0.97 |
| 1ヶ月の変化 | -22.19% |
| 3ヶ月変化 | -40.81% |
| 1年変化 | -32.14% |
| 3年間の変化 | -61.80% |
| 5年間の変化 | -14.45% |
| IPOからの変化 | 68.53% |
最新ニュース
分析記事 • May 15
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings
The most recent earnings report from Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) was disappointing for...
ナラティブの更新 • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Recent updates
分析記事 • May 15
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings
The most recent earnings report from Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) was disappointing for...ナラティブの更新 • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Seeking Alpha • Apr 30
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Summary Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset accelerating legacy generic erosion, resulting in flat or declining revenues. 2026 guidance has already been cut; gross margins are guided lower, and consensus estimates likely remain too high heading into Q1 earnings. I maintain a HOLD rating, leaning bearish, pending a clean AMP-007 launch or transformative business development. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 24
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.ナラティブの更新 • Apr 10
AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.ナラティブの更新 • Mar 26
AMPH: Softer Guidance And Execution Risk Will Shape Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate from $32.00 to $29.00. This reflects updated views on softer revenue guidance, lower projected profit margins, a slightly higher discount rate, and a higher assumed future P/E multiple in light of recent price target cuts to $30.00 from several firms.
ナラティブの更新 • Mar 12
AMPH: Softer Guidance And Pipeline Risk Will Still Support Future Upside
Analysts have modestly reduced their price targets on Amphastar Pharmaceuticals to $30, reflecting concerns about softer revenue guidance and pipeline execution risk. At the same time, recent product approvals and revised earnings assumptions support a slightly higher modeled fair value and P/E multiple in our framework.ナラティブの更新 • Feb 26
AMPH: Pipeline Execution Risk Will Cap Upside Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, citing cautious views on pipeline execution risk, even as they still see the shares as undervalued relative to peers and historical valuation. Analyst Commentary Recent research updates reflect a more cautious tone, with bearish analysts trimming price expectations even while acknowledging that Amphastar still trades at what they view as a discount to peers and its own history.ナラティブの更新 • Feb 09
AMPH: Pipeline Execution Risk Will Drive Cautious View Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31, reflecting a cautious view on pipeline execution risk, even as they see the shares as undervalued relative to historical and peer valuations. Analyst Commentary Bearish analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31 as coverage transitions, signaling a cautious stance on how the company can deliver on its current pipeline while justifying its valuation.ナラティブの更新 • Jan 25
AMPH: Buybacks And Pipeline Risk Will Shape Cautious Yet Balanced Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, reflecting updated views on revenue growth, margin assumptions, and future P/E expectations, along with ongoing caution around pipeline execution risk. Analyst Commentary Bearish analysts have taken a slightly more cautious stance, trimming the price target to US$30 from US$31 as coverage transitions to a new lead.ナラティブの更新 • Jan 11
AMPH: Pipeline Execution Risk Will Shape Cautious View Despite Buybacks
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31. The revised target reflects fresh coverage that balances a view of the shares as undervalued on comps and historical valuation with caution around pipeline execution risk.ナラティブの更新 • Dec 13
AMPH: Q3 Drug Trends And Buybacks Will Shape Balanced Near-Term Outlook
Analysts have modestly lowered their price target on Amphastar Pharmaceuticals to $31 from $32, citing recent Q3 pricing and volume trends for key drugs and a largely unchanged outlook for near term earnings and 2026 estimates. Analyst Commentary Bearish analysts have highlighted that the modest reduction in the price target reflects growing caution around the durability of Amphastar's recent performance, particularly in light of more muted pricing and volume trends observed in the third quarter.分析記事 • Jul 01
Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 7.6x might make it look like a...分析記事 • Apr 04
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 19
Amphastar Pharmaceuticals: A Gradual Strategy
Summary Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside. My strategy includes a 0.75x position weight and a gradual approach combining the stock with a Covered Call. Read the full article on Seeking Alpha分析記事 • Jan 03
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 16
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.9x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...分析記事 • Nov 28
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Oct 25
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Summary Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in 2026, limiting long-term revenue potential. BAQSIMI contributed $38.5 million in Q2 2024 sales, affirming its strategic acquisition from Eli Lilly. Amphastar’s heavy reliance on a few high-margin products, like glucagon and epinephrine, may limit future growth due to rising competition. I recommend holding Amphastar as current valuations seem fair, but growth prospects are uncertain due to product competition and patent expirations. Read the full article on Seeking Alpha分析記事 • Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 14.1x might make it look like a...Seeking Alpha • Sep 12
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Summary Amphastar Pharmaceuticals has seen significant growth since its 2014 IPO, with its stock price increasing over 500% to $45 per share. The acquisition of Baqsimi from Eli Lilly is a key revenue driver, but its long-term profitability remains uncertain due to milestone payments. Amphastar's revenue growth from epinephrine and Primatene Mist may not be sustainable, and the company faces intense competition in these markets. The pipeline's future is unclear, with several FDA rejections and no standout products, leading to a "Hold" rating on Amphastar stock. Read the full article on Seeking Alpha
新しいナラティブ • Sep 10
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.分析記事 • Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 01
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Summary AMPH has materially benefited from a variety of temporary factors across their key product lines that have largely gone unnoticed by investors, sending shares up ~100% over the last 3yrs. Amphastar’s glucagon business has benefited from shortages at Fresenius, which were recently rectified. Three new competitors are about to launch glucagon, turning this duopoly into a potential 5-player market. Epinephrine revenues should meaningfully disappoint as shortage benefits alleviate, a newly approved competitor ramps, and two potential competitors gain approval. The sole Orange Book patent on Primatene MIST, a key high margin product, expires in January 2026, which opens the door to material competition. Primatene is one of the few DTC products in its aisle without a generic. A handful of smaller “Other” products have been buoyed by a tornado which took out competitor Pfizer’s product warehousing. The magnitude of the benefit is larger than investors believe, and Pfizer is quickly returning to market. Read the full article on Seeking Alpha分析記事 • May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Seeking Alpha • May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Summary Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors. Read the full article on Seeking AlphaSeeking Alpha • May 15
Reassessing Amphastar Pharmaceuticals
Summary Amphastar Pharmaceuticals, Inc. stock is down approximately 30% this year, and the company reported mixed Q1 results last week. Despite the poor performance of the stock so far in 2024, there are some positives on the company and its stock. An updated analysis around Amphastar Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Mar 04
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Summary Amphastar Pharmaceuticals specializes in developing, manufacturing, and distributing pharmaceutical products, with a focus on strategic acquisitions. The company's portfolio includes high-margin products such as Primatene MIST and Glucagon Injection for severe hypoglycemia. Amphastar's pipeline includes promising upcoming products such as Rextovy, and its recent acquisition of Baqsimi enhances its position in diabetes management. AMPH's financials indicate manageable debt levels and the potential for continued revenue growth and profitability, reinforcing its investment appeal. My valuation analysis suggests AMPH is undervalued compared to peers, with strong business fundamentals supporting a "Strong Buy" rating. Read the full article on Seeking Alpha分析記事 • Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
With a price-to-earnings (or "P/E") ratio of 21.4x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...分析記事 • Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...株主還元
| AMPH | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | -11.2% | -12.9% | -0.9% |
| 1Y | -32.1% | 34.9% | 24.4% |
業界別リターン: AMPH過去 1 年間で34.9 % の収益を上げたUS Pharmaceuticals業界を下回りました。
リターン対市場: AMPHは、過去 1 年間で24.4 % のリターンを上げたUS市場を下回りました。
価格変動
| AMPH volatility | |
|---|---|
| AMPH Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: AMPH 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: AMPHの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 1,976 | Jack Zhang | www.amphastar.com |
バイオ医薬品会社であるアンファスター・ファーマシューティカルズ・インクは、米国、中国、フランスにおいて、ジェネリック医薬品および独自の注射剤、吸入剤、経鼻剤の開発、製造、販売、マーケティングを行っている。重篤な低血糖症の治療に緊急時に使用されるドライ点鼻薬「BAQSIMI」、間欠性喘息の軽度の症状を一時的に緩和するエピネフリン吸入製剤「Primatene MIST」、注射用緊急キット「Glucagon」、深部静脈血栓症の予防・治療用低分子ヘパリン注射剤「Enoxaparin」、オピオイド過剰摂取治療薬「REXTOVY」と「Naloxone」を提供している。同社はまた、副腎皮質機能不全患者のスクリーニングにおける診断薬として使用される凍結乾燥剤Cortrosyn、ウシ由来のヒアルロニダーゼ注射剤Amphadase、アレルギー反応用のエピネフリン注射剤も提供している；アトロピン、塩化カルシウム、ブドウ糖、エピネフリン、リドカイン、炭酸水素ナトリウムなどの緊急用注射器製品。さらに、気管支痙攣の治療または予防のための硫酸アルブテロール吸入エアゾール、慢性腎臓病患者の鉄欠乏性貧血の治療のための鉄補給剤であるスクロース鉄注射剤、毎日の骨粗鬆症治療の管理のためのテリパラチド注射剤、慢性閉塞性肺疾患に伴う気管支痙攣の維持治療のための抗コリン剤である臭化イプラトロピウムHFA吸入エアゾールを提供しています。さらに、同社は遺伝子組換えヒトインスリンやブタインスリン原薬などの原薬（API）製品を提供している。同社は1996年に設立され、カリフォルニア州ランチョクカモンガに本社を置いている。
Amphastar Pharmaceuticals, Inc. 基礎のまとめ
| AMPH 基礎統計学 | |
|---|---|
| 時価総額 | US$762.81m |
| 収益（TTM） | US$79.23m |
| 売上高(TTM) | US$720.53m |
9.4x
PER（株価収益率1.0x
P/SレシオAMPH は割高か？
公正価値と評価分析を参照収益と収入
| AMPH 損益計算書（TTM） | |
|---|---|
| 収益 | US$720.53m |
| 売上原価 | US$379.40m |
| 売上総利益 | US$341.13m |
| その他の費用 | US$261.90m |
| 収益 | US$79.23m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 1.80 |
| グロス・マージン | 47.34% |
| 純利益率 | 11.00% |
| 有利子負債／自己資本比率 | 79.0% |
AMPH の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/15 17:49 |
| 終値 | 2026/05/15 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Amphastar Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Pavan Patel | BofA Global Research |